Vir Biotechnology Files Definitive Proxy Materials
Ticker: VIR · Form: DEFA14A · Filed: Apr 16, 2026 · CIK: 0001706431
Sentiment: neutral
Topics: proxy-filing, corporate-governance
TL;DR
Vir Bio filed proxy docs 4/16/26. Standard shareholder stuff.
AI Summary
Vir Biotechnology, Inc. filed a Definitive Additional Materials (DEFA14A) on April 16, 2026. This filing contains proxy soliciting materials related to the company's business. The filing does not appear to contain specific financial figures or executive compensation details within the provided text.
Why It Matters
This filing indicates that Vir Biotechnology is actively engaging with its shareholders regarding corporate matters, which is a standard part of corporate governance and shareholder communication.
Risk Assessment
Risk Level: low — The filing is a routine DEFA14A, which typically contains standard proxy materials and does not inherently signal new risks.
Key Players & Entities
- Vir Biotechnology, Inc. (company) — Filer of the DEFA14A
- 0001706431 (company) — CIK number for Vir Biotechnology, Inc.
- 0001628280-26-025380 (filing_id) — SEC Accession Number for the DEFA14A filing
- 2026-04-16 (date) — Filing date of the DEFA14A
FAQ
What type of SEC filing is this?
This is a DEFA14A filing, which stands for Additional definitive proxy soliciting materials and Rule 14(a)(12) material.
Who is the filer of this document?
The filer is Vir Biotechnology, Inc., with CIK number 0001706431.
When was this filing accepted by the SEC?
The filing was accepted on 2026-04-16 at 08:49:02.
What is the company's business address?
The business address is 1800 OWENS STREET SUITE 900 SAN FRANCISCO CA 94158.
What is the SIC code for Vir Biotechnology, Inc.?
The SIC code is 2836, which pertains to Biological Products, (No Diagnostic Substances).
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 16, 2026 regarding Vir Biotechnology, Inc. (VIR).